L. Aukerman

In-situ self-assembling protein polymer gel systems for administration, delivery, and release of drugs.

J. Cappello, J. Crissman, G. Textor, 1998, Journal of controlled release : official journal of the Controlled Release Society.

T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.

J. Mulé, M. Giedlin, J. Chamberlain, 2001, Cancer research.

Cell-dependent Antitumor Immunity Mediated by Secondary Lymphoid Tissue Chemokine : Augmentation of Dendritic Cell-based Immunotherapy 1

J. Mulé, M. Giedlin, J. Chamberlain, 2001 .

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

J. Byrd, I. Flinn, T. Kipps, 2006 .

Anti‐HCV therapies in chimeric scid‐Alb/uPA mice parallel outcomes in human clinical application

Z. Ni, D. Tyrrell, A. Weiner, 2006, Hepatology.

Boundary layer infusion of basic fibroblast growth factor accelerates intimal hyperplasia in endarterectomized canine artery.

J. Li, A. Lumsden, S. Hanson, 1997, The Journal of surgical research.

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

S. Jagannath, S. Girish, A. Solinger, 2006 .

Antagonist Anti-CD40 Monoclonal Antibody, CHIR-12.12, Inhibits Growth of a Rituximab-Resistant NHL Xenograft Model and Achieves Synergistic Activity When Combined with Ineffective Rituximab.

M. Patawaran, B. Jallal, M. Luqman, 2004 .

Keratinocyte Growth Factor Protects Mice from Chemotherapy and Radiation-induced Gastrointestinal Injury and Mortality1

Catherine, D. Lacey, K. Rex, 2006 .